Latest News and Press Releases

Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive...

Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO® and ALOXI® in Germany Lugano, Switzerland – January 8, 2025 – Helsinn Group (“Helsinn”), a global...

Helsinn Group appoints Riccardo Carbucicchio to the Board of Directors Lugano, Switzerland – September 19, 2024 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of...

Helsinn Group announces AKYNZEO® (fosnetupitant/palonosetron) injection is now available in a ready-to-use vial in the US Lugano, Switzerland – June 24, 2024 – Helsinn Group (“Helsinn”), a global...

Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...

Helsinn and Angelini Pharma sign a partnership agreement renewal to commercialize AULIN® and MESULID® in Bulgaria, Czech Republic, Hungary, Poland, Romania and Slovak Republic Lugano...

New York, Dec. 06, 2023 (GLOBE NEWSWIRE) -- The global vaso occlusive crisis market size is projected to expand at 8% CAGR between 2024 and 2036. The market is expected to garner a revenue of USD 20...

Wilmington, Delaware, United States, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The acute kidney injury treatment market stood at US$ 1.5 Bn in 2021. TMR projects that the...

NEW YORK, Feb. 06, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company based on proprietary transdermal delivery, today announced the minipig safety and...

NEW YORK, Jan. 04, 2019 (GLOBE NEWSWIRE) -- ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult...